Evaluation of pre-hospital use of a valsalva assist device in the emergency treatment of supraventricular tachycardia [EVADE]: a randomised controlled feasibility trial

Abstract Background The valsalva manoeuvre is an internationally recommended initial treatment for supraventricular tachycardia (SVT). The pre-hospital use of a valsalva assist device, to help deliver this manoeuvre, could improve cardioversion rates and reduce the need for patients to attend hospit...

Full description

Bibliographic Details
Main Authors: Andrew Appelboam, Jonathan Green, Paul Ewings, Sarah Black, EVADE study SWASFT collaborators
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Pilot and Feasibility Studies
Subjects:
Online Access:http://link.springer.com/article/10.1186/s40814-020-00616-y
_version_ 1818507995976302592
author Andrew Appelboam
Jonathan Green
Paul Ewings
Sarah Black
EVADE study SWASFT collaborators
author_facet Andrew Appelboam
Jonathan Green
Paul Ewings
Sarah Black
EVADE study SWASFT collaborators
author_sort Andrew Appelboam
collection DOAJ
description Abstract Background The valsalva manoeuvre is an internationally recommended initial treatment for supraventricular tachycardia (SVT). The pre-hospital use of a valsalva assist device, to help deliver this manoeuvre, could improve cardioversion rates and reduce the need for patients to attend hospital. Methods We conducted a randomised controlled feasibility trial comparing ambulance clinician use of a valsalva assist device versus standard care to treat adult patients presenting to an ambulance service in the south west of England. Eligible consenting participants were randomised 1:1 to device or standard care with trial procedures mirroring a proposed definitive trial. Feasibility was assessed upon ambulance clinician and participant recruitment rates and feedback, data completeness and potential future primary outcome rates. Results Over a 6 months period (1 July to 31 December 2018), 276 (23%) of 1183 eligible ambulance clinicians were trained and they recruited 34 participants; approximately 10% of patients presenting with suspected SVT during that time. Seventeen participants were randomised to each arm and all underwent their allocated valsalva strain method. All trial data and 63/68 (93%) of pre and post-valsalva ECGs were available. Seven (21%) participants had ineligible initial rhythms on retrospective expert ECG review. Valsalva assist device use was associated with cardioversion and non-conveyance in 4 (24%) and 2 (12%) participants respectively. No participants assigned to standard care were cardioverted and all were conveyed. Participant feedback highlighted the challenges of retaining trial information during an SVT attack. Conclusions The trial achieved efficient clinician training, randomisation and data collection, and there was an encouraging effect signal associated with device use. However, trial design changes should be considered to address the relatively small proportion of eligible patients recruited and challenges identified with consent and confirmation of cardioversion as a primary outcome. Trial registration The trial was registered with ClinicalTrials.gov ( NCT03514628 ) on 2 May 2018.
first_indexed 2024-12-10T22:25:49Z
format Article
id doaj.art-f5db176a855e42868e10aca7f066e798
institution Directory Open Access Journal
issn 2055-5784
language English
last_indexed 2024-12-10T22:25:49Z
publishDate 2020-05-01
publisher BMC
record_format Article
series Pilot and Feasibility Studies
spelling doaj.art-f5db176a855e42868e10aca7f066e7982022-12-22T01:31:11ZengBMCPilot and Feasibility Studies2055-57842020-05-01611910.1186/s40814-020-00616-yEvaluation of pre-hospital use of a valsalva assist device in the emergency treatment of supraventricular tachycardia [EVADE]: a randomised controlled feasibility trialAndrew Appelboam0Jonathan Green1Paul Ewings2Sarah Black3EVADE study SWASFT collaboratorsUniversity of Exeter Medical School, St Luke’sSouth West Ambulance Service Foundation TrustUniversity of Exeter Medical School, St Luke’sSouth West Ambulance Service Foundation TrustAbstract Background The valsalva manoeuvre is an internationally recommended initial treatment for supraventricular tachycardia (SVT). The pre-hospital use of a valsalva assist device, to help deliver this manoeuvre, could improve cardioversion rates and reduce the need for patients to attend hospital. Methods We conducted a randomised controlled feasibility trial comparing ambulance clinician use of a valsalva assist device versus standard care to treat adult patients presenting to an ambulance service in the south west of England. Eligible consenting participants were randomised 1:1 to device or standard care with trial procedures mirroring a proposed definitive trial. Feasibility was assessed upon ambulance clinician and participant recruitment rates and feedback, data completeness and potential future primary outcome rates. Results Over a 6 months period (1 July to 31 December 2018), 276 (23%) of 1183 eligible ambulance clinicians were trained and they recruited 34 participants; approximately 10% of patients presenting with suspected SVT during that time. Seventeen participants were randomised to each arm and all underwent their allocated valsalva strain method. All trial data and 63/68 (93%) of pre and post-valsalva ECGs were available. Seven (21%) participants had ineligible initial rhythms on retrospective expert ECG review. Valsalva assist device use was associated with cardioversion and non-conveyance in 4 (24%) and 2 (12%) participants respectively. No participants assigned to standard care were cardioverted and all were conveyed. Participant feedback highlighted the challenges of retaining trial information during an SVT attack. Conclusions The trial achieved efficient clinician training, randomisation and data collection, and there was an encouraging effect signal associated with device use. However, trial design changes should be considered to address the relatively small proportion of eligible patients recruited and challenges identified with consent and confirmation of cardioversion as a primary outcome. Trial registration The trial was registered with ClinicalTrials.gov ( NCT03514628 ) on 2 May 2018.http://link.springer.com/article/10.1186/s40814-020-00616-ySupraventricular tachycardiaValsalva manoeuvreEmergency careValsalva assist device
spellingShingle Andrew Appelboam
Jonathan Green
Paul Ewings
Sarah Black
EVADE study SWASFT collaborators
Evaluation of pre-hospital use of a valsalva assist device in the emergency treatment of supraventricular tachycardia [EVADE]: a randomised controlled feasibility trial
Pilot and Feasibility Studies
Supraventricular tachycardia
Valsalva manoeuvre
Emergency care
Valsalva assist device
title Evaluation of pre-hospital use of a valsalva assist device in the emergency treatment of supraventricular tachycardia [EVADE]: a randomised controlled feasibility trial
title_full Evaluation of pre-hospital use of a valsalva assist device in the emergency treatment of supraventricular tachycardia [EVADE]: a randomised controlled feasibility trial
title_fullStr Evaluation of pre-hospital use of a valsalva assist device in the emergency treatment of supraventricular tachycardia [EVADE]: a randomised controlled feasibility trial
title_full_unstemmed Evaluation of pre-hospital use of a valsalva assist device in the emergency treatment of supraventricular tachycardia [EVADE]: a randomised controlled feasibility trial
title_short Evaluation of pre-hospital use of a valsalva assist device in the emergency treatment of supraventricular tachycardia [EVADE]: a randomised controlled feasibility trial
title_sort evaluation of pre hospital use of a valsalva assist device in the emergency treatment of supraventricular tachycardia evade a randomised controlled feasibility trial
topic Supraventricular tachycardia
Valsalva manoeuvre
Emergency care
Valsalva assist device
url http://link.springer.com/article/10.1186/s40814-020-00616-y
work_keys_str_mv AT andrewappelboam evaluationofprehospitaluseofavalsalvaassistdeviceintheemergencytreatmentofsupraventriculartachycardiaevadearandomisedcontrolledfeasibilitytrial
AT jonathangreen evaluationofprehospitaluseofavalsalvaassistdeviceintheemergencytreatmentofsupraventriculartachycardiaevadearandomisedcontrolledfeasibilitytrial
AT paulewings evaluationofprehospitaluseofavalsalvaassistdeviceintheemergencytreatmentofsupraventriculartachycardiaevadearandomisedcontrolledfeasibilitytrial
AT sarahblack evaluationofprehospitaluseofavalsalvaassistdeviceintheemergencytreatmentofsupraventriculartachycardiaevadearandomisedcontrolledfeasibilitytrial
AT evadestudyswasftcollaborators evaluationofprehospitaluseofavalsalvaassistdeviceintheemergencytreatmentofsupraventriculartachycardiaevadearandomisedcontrolledfeasibilitytrial